文献速递消化道肿瘤放疗

全程新辅助治疗(CAO/ARO/AIO-12)与强化新辅助及辅助治疗(CAO/ARO/AIO-04)后的临床结局:两项多中心随机II/III期试验的比较

Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
PubMed 文献 · Radiother Oncol · 2022-12-23

本文比较CAO/ARO/AIO-04 III期试验实验组607例接受强化5-FU/奥沙利铂新辅助放化疗后辅助化疗的患者与CAO/ARO/AIO-12 II期试验306例接受全程新辅助治疗(TNT)的患者。TNT组病理完全缓解率显著更高(25.3% vs 17.3%,P=0.04),术后并发症更少;中位随访46个月后总队列、各亚组及倾向评分匹配后临床结局均无显著差异。作者认为尽管存在试验间比较的局限性,TNT未改善长期肿瘤学结局。

要点

  • TNT组病理完全缓解率25.3%,显著高于CAO/ARO/AIO-04实验组的17.3%(P=0.04)。
  • CAO/ARO/AIO-12试验术后并发症较CAO/ARO/AIO-04试验更少见。
  • 中位随访46个月,总队列、亚组及倾向评分匹配后临床结局均无显著差异。

核心结论

  • 尽管存在试验间比较的局限性,TNT与CAO/ARO/AIO-04试验的强化新辅助放化疗后辅助化疗相比,未改善长期肿瘤学结局。
  • TNT后提高的缓解率为进一步在选择性局部晚期直肠癌患者中探索器官保留提供了有吸引力的选择。

研究设计与样本

  • 本研究为CAO/ARO/AIO-04 III期试验实验组607例与CAO/ARO/AIO-12 II期试验306例之间的二次比较。
  • CAO/ARO/AIO-04实验组接受强化5-FU/奥沙利铂新辅助放化疗后辅助化疗,CAO/ARO/AIO-12组接受全程新辅助治疗。
  • 采用Pearson卡方检验或Mann-Whitney U检验比较临床病理特征、手术质量及术后并发症,采用log-rank检验、Gray检验及多因素Cox回归分析肿瘤学结局,并进行亚组分析和倾向评分匹配。

主要发现

  • 接受放化疗后巩固化疗的患者病理完全缓解率显著高于CAO/ARO/AIO-04试验实验组患者(25.3% vs 17.3%,P=0.04)。
  • CAO/ARO/AIO-12试验术后并发症较CAO/ARO/AIO-04试验更少见。
  • 中位随访46个月后,总队列、任何亚组及倾向评分匹配后临床结局均无显著差异。
  • 多因素分析中,CAO/ARO/AIO-04试验实验组与CAO/ARO/AIO-12试验治疗组无病生存期相似(对比A组:HR 0.92 [95%CI 0.62-1.37],P=0.69;对比B组:HR 1.06 [95%CI 0.72-1.58],P=0.76)。

局限性

  • 原文指出存在试验间比较的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total neoadjuvant therapy (TNT) can enhance local tumor regression, but its survival benefits compared to intensified chemoradiotherapy (CRT) followed by adjuvant chemotherapy (CT) remain unclear. METHODS: This is a secondary comparison between 607 patients treated with intensified 5-FU/Oxaliplatin neoadjuvant CRT and adjuvant CT within the experimental arm of the CAO/ARO/AIO-04 phase III trial, and 306 patients treated with TNT within the CAO/ARO/AIO-12 phase II trial. Comparison between clinical-pathological characteristics, surgical quality, and post-surgical complications were analyzed using the Pearson's Chi-squared or Mann-Whitney U test. Oncological outcome was examined with log-rank, Gray's test, and multivariate cox regression. In addition, further subgroup analyses and propensity score matching were performed to optimize the balance of baseline covariates. FINDINGS: Patients treated with CRT followed by consolidation CT had a significantly higher rate of pathological complete remission (pCR) compared to patients treated within the experimental arm of the CAO/ARO/AIO-04 trial (25.3 % vs 17.3 %, P = 0.04). Post-surgical complications were less common in the CAO/ARO/AIO-12 trial. After a median follow-up of 46 months, clinical outcome did not differ significantly in the overall cohort, in any subgroup or after propensity score matching. In multivariate analysis, disease-free survival (DFS) was similar between the experimental arm of the CAO/ARO/AIO-04 trial and treatments arms of the CAO/ARO/AIO-12 trial (vs arm A: HR 0.92 [95 % CI 0.62-1.37], P = 0.69; vs arm B: HR 1.06 [95 % CI 0.72-1.58], P = 0.76). INTERPRETATION: Notwithstanding the limitations of intertrial comparison, TNT did not improve long term oncological outcome in our study compared to the intensified neoadjuvant CRT and adjuvant CT treatment in the CAO/ARO/AIO-04 trial. Improved response rates after TNT offers an attractive option to explore organ preservation in selective patients with locally advanced rectal cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Diefenhardt M, Fleischmann M, Martin D, et al. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials. Radiother Oncol. 2022. PMID: 36572280. doi:10.1016/j.radonc.2022.109455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。